Skip to main content
CNTA
NASDAQ Life Sciences

Former Officer Files Intent to Sell $52.6M in Centessa Pharmaceuticals Stock

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
8
Price
$23.23
Mkt Cap
$3.081B
52W Low
$9.6
52W High
$30.58
Market data snapshot near publication time

summarizeSummary

A former officer of Centessa Pharmaceuticals plc has filed a Form 144 indicating an intent to sell approximately $52.6 million worth of Class A Common Stock, following over $56 million in sales in the past three months.


check_boxKey Events

  • Proposed Stock Sale

    A former officer, Saurabh Saha, has filed a Form 144 to sell 2,300,000 shares of Class A Common Stock, valued at approximately $52.6 million.

  • Recent Insider Sales

    This proposed sale follows previous sales by the same individual totaling 2,500,000 shares, generating gross proceeds of $56.2 million over the past three months.

  • Insider Role

    The filer is identified as a former officer of Centessa Pharmaceuticals plc.

  • Stated Purpose

    The proceeds from the proposed sale may be used to fund the exercise and hold of stock options, including related withholding taxes.


auto_awesomeAnalysis

The filing by Saurabh Saha, a former officer, signals a substantial reduction in his holdings of Centessa Pharmaceuticals stock. The proposed sale of $52.6 million, combined with over $56 million in sales over the last three months, represents a significant liquidation of shares by a key insider. While the filing mentions the proceeds may fund stock option exercises and related taxes, the sheer magnitude of the intended and recent sales could be perceived negatively by the market, suggesting a lack of long-term conviction from a former executive. Investors should monitor for the actual execution of these sales and any further insider activity.

At the time of this filing, CNTA was trading at $23.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $9.60 to $30.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CNTA - Latest Insights

CNTA
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
CNTA
Mar 31, 2026, 4:38 PM EDT
Filing Type: DEFA14A
Importance Score:
10
CNTA
Mar 31, 2026, 4:31 PM EDT
Filing Type: 10-K
Importance Score:
10
CNTA
Mar 31, 2026, 8:18 AM EDT
Filing Type: DFAN14A
Importance Score:
10
CNTA
Mar 31, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
CNTA
Feb 13, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
CNTA
Jan 21, 2026, 4:58 PM EST
Filing Type: 144
Importance Score:
8
CNTA
Jan 06, 2026, 6:23 PM EST
Filing Type: 8-K/A
Importance Score:
7
CNTA
Jan 02, 2026, 4:45 PM EST
Filing Type: 144
Importance Score:
9